William S. Loui

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
4116 Background: HCC tumors are highly vascular and over express VEGF. The monoclonal antibody BEV and the oral multi-kinase inhibitor SOR inhibit VEGF-induced angiogenesis and the associated(More)
We conducted an experimental pilot study in an oncology clinic in Honolulu, Hawai'i to determine the effect of a culturally-tailored educational DVD on cancer clinical trial participation among(More)
Angiogenesis has been a major target of novel drug development in hepatocellular carcinoma (HCC). It is hypothesized that the combination of two antiangiogenic agents, sorafenib and bevacizumab, will(More)
  • 1